Bedaquiline inhibits the yeast and human mitochondrial ATP synthases

Bedaquiline (BDQ, Sirturo) has been approved to treat multidrug resistant forms of Mycobacterium tuberculosis. Prior studies suggested that BDQ was a selective inhibitor of the ATP synthase from M. tuberculosis. However, Sirturo treatment leads to an increased risk of cardiac arrhythmias and death,...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Min, Zhou, Wenchang, Patel, Hiral, Srivastava, Anurag P., Symersky, Jindrich, Bonar, Michał M., Faraldo-Gómez, José D., Liao, Maofu, Mueller, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438494/
https://www.ncbi.nlm.nih.gov/pubmed/32814813
http://dx.doi.org/10.1038/s42003-020-01173-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438494/
https://www.ncbi.nlm.nih.gov/pubmed/32814813
http://dx.doi.org/10.1038/s42003-020-01173-z

Ejemplares similares